The pursuit of market outperformance leads investors to the practice of hand-picking stocks. Skillful choices can be a catalyst for significant wealth enhancement.
The closing price of Esperion Therapeutics Inc (NASDAQ: ESPR) was $0.98 for the day, down -7.10% from the previous closing price of $1.05. In other words, the price has decreased by -$7.10 from its previous closing price. On the day, 4.73 million shares were traded.
Ratios:
Our analysis of ESPR’s different ratios will help us gain a deeper understanding of the company. For the most recent quarter (mrq), Quick Ratio is recorded 0.99 and its Current Ratio is at 1.37.
Upgrades & Downgrades
In addition, analysts’ ratings and any changes thereto give investors an idea of the stock’s future direction. In the most recent recommendation for this company, Goldman on December 18, 2024, initiated with a Neutral rating and assigned the stock a target price of $4.
On December 17, 2024, Cantor Fitzgerald started tracking the stock assigning a Overweight rating and target price of $8.
BofA Securities Downgraded its Neutral to Underperform on June 20, 2024, while the target price for the stock was maintained at $2.50.
Insider Transactions:
Also, insider trades can serve as a great indicator of what management thinks about the future direction of a stock’s price. A recent insider transaction in this stock occurred on Apr 17 ’25 when Warren Eric sold 108 shares for $0.98 per share. The transaction valued at 106 led to the insider holds 370,218 shares of the business.
Halladay Benjamin sold 8 shares of ESPR for $8 on Apr 17 ’25. The Chief Financial Officer now owns 481,702 shares after completing the transaction at $0.96 per share. On Apr 17 ’25, another insider, Halladay Benjamin, who serves as the Officer of the company, bought 8 shares for $0.96 each.
Valuation Measures:
For the stock, the TTM Price-to-Sale (P/S) ratio is 0.58.
Stock Price History:
Over the past 52 weeks, ESPR has reached a high of $3.94, while it has fallen to a 52-week low of $0.82. The 50-Day Moving Average of the stock is -26.53%, while the 200-Day Moving Average is calculated to be -49.07%.
Shares Statistics:
A total of 195.85M shares are outstanding, with a floating share count of 194.67M. Insiders hold about 1.76% of the company’s shares, while institutions hold 58.73% stake in the company.
Earnings Estimates
The consensus estimate for the next quarter is $0, with high estimates of $0 and low estimates of $0.
Analysts are recommending an EPS of between -$0.36 and -$0.36 for the fiscal current year, implying an average EPS of -$0.36. EPS for the following year is -$0.51, with 2.0 analysts recommending between -$0.43 and -$0.59.
Revenue Estimates
It is expected that $90B in revenue will be generated in the current quarter, according to 2 analysts. It ranges from a high estimate of $59.79M to a low estimate of $55.1M. As of the current estimate, Esperion Therapeutics Inc’s year-ago sales were $73.83MFor the next quarter, 2 analysts are estimating revenue of $90.51M. There is a high estimate of $119.1M for the next quarter, whereas the lowest estimate is $61.91M.
A total of 4 analysts have provided revenue estimates for ESPR’s current fiscal year. The highest revenue estimate was $362.1M, while the lowest revenue estimate was $297.42M, resulting in an average revenue estimate of $317.73M. In the same quarter a year ago, actual revenue was $332.31MBased on 7 analysts’ estimates, the company’s revenue will be $301M in the next fiscal year. The high estimate is $366M and the low estimate is $197.64M.
